Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Other Non-Current Liabilities (2016 - 2025)

Palisade Bio (PALI) has disclosed Other Non-Current Liabilities for 14 consecutive years, with $283000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 14050.0% to $283000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $283000.0, a 14050.0% increase, with the full-year FY2024 number at $150000.0, up 145.9% from a year prior.
  • Other Non-Current Liabilities was $283000.0 for Q3 2025 at Palisade Bio, up from $75000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $20.5 million in Q2 2021 to a low of $2000.0 in Q3 2024.
  • A 5-year average of $2.4 million and a median of $160601.0 in 2021 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: soared 32677.09% in 2021, then tumbled 99.7% in 2023.
  • Palisade Bio's Other Non-Current Liabilities stood at $9.4 million in 2021, then crashed by 98.09% to $180000.0 in 2022, then plummeted by 66.11% to $61000.0 in 2023, then surged by 145.9% to $150000.0 in 2024, then surged by 88.67% to $283000.0 in 2025.
  • Per Business Quant, the three most recent readings for PALI's Other Non-Current Liabilities are $283000.0 (Q3 2025), $75000.0 (Q2 2025), and $2000.0 (Q1 2025).